Bionano Genomics (NASDAQ:BNGO) Receives Sector Perform Rating from Scotiabank

Bionano Genomics (NASDAQ:BNGO)‘s stock had its “sector perform” rating reaffirmed by Scotiabank in a note issued to investors on Wednesday, Benzinga reports. They presently have a $1.00 price target on the stock, down from their previous price target of $6.00. Scotiabank’s price objective suggests a potential upside of 95.08% from the company’s previous close.

Separately, BTIG Research dropped their price target on shares of Bionano Genomics from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Thursday, May 16th.

Bionano Genomics Stock Down 1.8 %

Shares of NASDAQ BNGO opened at $0.51 on Wednesday. The firm’s 50 day moving average price is $0.59 and its 200 day moving average price is $0.87. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.13 and a current ratio of 1.46. The firm has a market cap of $34.27 million, a P/E ratio of -0.09 and a beta of 2.40. Bionano Genomics has a 1 year low of $0.31 and a 1 year high of $4.20.

Institutional Trading of Bionano Genomics

A number of institutional investors have recently modified their holdings of BNGO. Armistice Capital LLC acquired a new position in Bionano Genomics during the second quarter valued at approximately $1,138,000. Cetera Advisors LLC acquired a new position in shares of Bionano Genomics during the 1st quarter valued at $163,000. Virtu Financial LLC purchased a new stake in Bionano Genomics during the 1st quarter worth $36,000. Price T Rowe Associates Inc. MD increased its holdings in Bionano Genomics by 123.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock valued at $79,000 after purchasing an additional 38,900 shares in the last quarter. Finally, GSA Capital Partners LLP raised its position in Bionano Genomics by 532.7% in the first quarter. GSA Capital Partners LLP now owns 549,789 shares of the company’s stock valued at $610,000 after purchasing an additional 462,887 shares during the period. Hedge funds and other institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.